Clinical Trial Update: A Pilot Study to Assess the Feasibility of Switching, Individuals Receiving Atripla With Continuing Central Nervous System (CNS) Toxicity, to a Fixed Dose Combination of Tenofovir/Emtricitabine/Rilpivirine [Phase 3]

View source ↗

Summary

A Phase 3 pilot study evaluated the feasibility of switching HIV patients from Atripla to a fixed-dose combination of tenofovir disoproxil fumarate/emtricitabin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Atripla (efavirenz/emtricitabine/tenofovir disoproxil fumarate)
• Tenofovir disoproxil fumarate/emtricitabine/rilpivirine (tenofovir disoproxil fumarate/emtricitabine/rilpivirine)

Snippet

Sponsor: St Stephens Aids Trust | Conditions: HIV | Phase 3 | Status: COMPLETED